Physician profile
Gary E Raffel
NPI 1396747432
$510.94
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $94.31 · 2021: $12.43.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $105.90 | 2019-2020 | |
| Novo Nordisk INC | $88.14 | 2019-2021 | |
| Biofire Diagnostics, LLC | $77.02 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $72.47 | 2019-2020 | |
| Astellas Pharma US INC | $48.87 | 2019-2020 | |
| Lilly USA, LLC | $28.59 | 2019-2020 | |
| Mylan Specialty L.P. | $23.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.47 | 2019 | |
| Pfizer INC. | $14.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Raffel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.